Labcorp Holdings Inc.

LH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LH stands at 22.4B. In comparison, NVST has a market cap of 4.4B. Regarding current trading prices, LH is priced at $269.51, while NVST trades at $26.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LH currently has a P/E ratio of 25.78, whereas NVST's P/E ratio is 95.93. In terms of profitability, LH's ROE is +0.10%, compared to NVST's ROE of +0.02%. Regarding short-term risk, LH is less volatile compared to NVST. This indicates potentially lower risk in terms of short-term price fluctuations for LH.Check NVST's competition here

LH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LH stands at 22.4B. In comparison, HIMS has a market cap of 3.5B. Regarding current trading prices, LH is priced at $269.51, while HIMS trades at $21.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LH currently has a P/E ratio of 25.78, whereas HIMS's P/E ratio is 30.88. In terms of profitability, LH's ROE is +0.10%, compared to HIMS's ROE of +0.23%. Regarding short-term risk, LH is less volatile compared to HIMS. This indicates potentially lower risk in terms of short-term price fluctuations for LH.Check HIMS's competition here

LH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LH stands at 22.4B. In comparison, CON has a market cap of 2.9B. Regarding current trading prices, LH is priced at $269.51, while CON trades at $22.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LH currently has a P/E ratio of 25.78, whereas CON's P/E ratio is 19.50. In terms of profitability, LH's ROE is +0.10%, compared to CON's ROE of +0.47%. Regarding short-term risk, LH is less volatile compared to CON. This indicates potentially lower risk in terms of short-term price fluctuations for LH.Check CON's competition here

LH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LH stands at 22.4B. In comparison, BBNX has a market cap of 470.9M. Regarding current trading prices, LH is priced at $269.51, while BBNX trades at $10.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LH currently has a P/E ratio of 25.78, whereas BBNX's P/E ratio is -5.86. In terms of profitability, LH's ROE is +0.10%, compared to BBNX's ROE of -0.24%. Regarding short-term risk, LH is less volatile compared to BBNX. This indicates potentially lower risk in terms of short-term price fluctuations for LH.Check BBNX's competition here

LH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LH stands at 22.4B. In comparison, CV has a market cap of 239.8M. Regarding current trading prices, LH is priced at $269.51, while CV trades at $5.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LH currently has a P/E ratio of 25.78, whereas CV's P/E ratio is -10.89. In terms of profitability, LH's ROE is +0.10%, compared to CV's ROE of +0.49%. Regarding short-term risk, LH is less volatile compared to CV. This indicates potentially lower risk in terms of short-term price fluctuations for LH.Check CV's competition here

LH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LH stands at 22.4B. In comparison, NAKA has a market cap of 97M. Regarding current trading prices, LH is priced at $269.51, while NAKA trades at $0.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LH currently has a P/E ratio of 25.78, whereas NAKA's P/E ratio is -0.18. In terms of profitability, LH's ROE is +0.10%, compared to NAKA's ROE of -0.74%. Regarding short-term risk, LH is less volatile compared to NAKA. This indicates potentially lower risk in terms of short-term price fluctuations for LH.Check NAKA's competition here

LH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LH stands at 22.4B. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, LH is priced at $269.51, while KDLY trades at $11.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LH currently has a P/E ratio of 25.78, whereas KDLY's P/E ratio is -15.48. In terms of profitability, LH's ROE is +0.10%, compared to KDLY's ROE of -0.74%. Regarding short-term risk, LH is less volatile compared to KDLY. This indicates potentially lower risk in terms of short-term price fluctuations for LH.Check KDLY's competition here

LH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LH stands at 22.4B. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, LH is priced at $269.51, while NEUE trades at $6.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LH currently has a P/E ratio of 25.78, whereas NEUE's P/E ratio is -0.38. In terms of profitability, LH's ROE is +0.10%, compared to NEUE's ROE of +0.22%. Regarding short-term risk, LH is more volatile compared to NEUE. This indicates potentially higher risk in terms of short-term price fluctuations for LH.Check NEUE's competition here

LH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LH stands at 22.4B. In comparison, PARK has a market cap of 38.2M. Regarding current trading prices, LH is priced at $269.51, while PARK trades at $18.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LH currently has a P/E ratio of 25.78, whereas PARK's P/E ratio is -109.11. In terms of profitability, LH's ROE is +0.10%, compared to PARK's ROE of -0.07%. Regarding short-term risk, LH is less volatile compared to PARK. This indicates potentially lower risk in terms of short-term price fluctuations for LH.Check PARK's competition here

LH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LH stands at 22.4B. In comparison, BRK has a market cap of 11.6M. Regarding current trading prices, LH is priced at $269.51, while BRK trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LH currently has a P/E ratio of 25.78, whereas BRK's P/E ratio is N/A. In terms of profitability, LH's ROE is +0.10%, compared to BRK's ROE of N/A. Regarding short-term risk, LH is less volatile compared to BRK. This indicates potentially lower risk in terms of short-term price fluctuations for LH.Check BRK's competition here

LH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LH stands at 22.4B. In comparison, PFSA has a market cap of 495.7K. Regarding current trading prices, LH is priced at $269.51, while PFSA trades at $0.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LH currently has a P/E ratio of 25.78, whereas PFSA's P/E ratio is -0.02. In terms of profitability, LH's ROE is +0.10%, compared to PFSA's ROE of +0.90%. Regarding short-term risk, LH is less volatile compared to PFSA. This indicates potentially lower risk in terms of short-term price fluctuations for LH.Check PFSA's competition here

LH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LH stands at 22.4B. In comparison, MEDC has a market cap of 0. Regarding current trading prices, LH is priced at $269.51, while MEDC trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LH currently has a P/E ratio of 25.78, whereas MEDC's P/E ratio is N/A. In terms of profitability, LH's ROE is +0.10%, compared to MEDC's ROE of N/A. Regarding short-term risk, LH is less volatile compared to MEDC. This indicates potentially lower risk in terms of short-term price fluctuations for LH.Check MEDC's competition here

LH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LH stands at 22.4B. In comparison, SIRO has a market cap of 0. Regarding current trading prices, LH is priced at $269.51, while SIRO trades at $109.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LH currently has a P/E ratio of 25.78, whereas SIRO's P/E ratio is N/A. In terms of profitability, LH's ROE is +0.10%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, LH is less volatile compared to SIRO. This indicates potentially lower risk in terms of short-term price fluctuations for LH.Check SIRO's competition here